Executive Summary
Over the past 24 hours, 12 filings reveal a severe wave of Nasdaq and NYSE American trading suspensions and delisting risks, concentrated among micro-cap biotech and healthcare companies. The dominant theme is acute financial distress, with 10 out of 12 companies reporting negative equity or failing minimum bid price rules, and 6 receiving new deficiency notices on June 9-12, 2026.
Period-over-period comparisons show a stark pattern: Soligenix's Phase 3 trial futility, La Rosa's negative equity of $(1.85M), and Wellgistics' $(12.45M) deficit highlight a sector-wide liquidity crisis. Insider activity is notably absent, with no insider buying detected across any filing, signaling a lack of management conviction. Forward-looking data reveals a compressed catalyst calendar: 7 companies face critical compliance deadlines between October and December 2026, with Genprex already ineligible for a grace period due to a prior reverse split. The most critical development is the NYSE American delisting of Perfect Moment Ltd., which chose not to appeal, setting a precedent for voluntary OTC transitions. The market implication is clear: investors should expect a cascade of delistings in H2 2026, with significant downside risk for common equity holders.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 8-K
Tracking the trend? Catch up on the prior US SEC Trading Suspension Halt Orders digest from June 04, 2026.
Investment Signals (10)
- Laser Photonics Corp ↓ (BULLISH)▲
Regained Nasdaq compliance on June 12, 2026 by filing its delinquent Form 10-Q, closing a non-compliance matter in just 22 days (May 21 to June 11). This rapid resolution signals strong internal controls and management responsiveness, a bullish outlier in a sea of distress
- BioCardia, Inc. ↓ (BULLISH)▲
Raised $4.9M net proceeds via ATM offering at an average price of $1.27 (June 5 average $1.279), believing it has regained compliance with the $2.5M equity requirement. The offering was executed at near-market prices with minimal dilution, suggesting investor confidence in the turnaround plan
- Wellgistics Health, Inc. ↓ (BULLISH)▲
Regained compliance with the minimum bid price rule on June 9, 2026 after 10 consecutive days above $1.00, while simultaneously pursuing a merger with DataVault AI that would create pro forma equity of ~$40M. This dual catalyst (compliance + M&A) creates a potential re-rating opportunity
- BiomX Inc. ↓ (BULLISH)▲
Received NYSE Regulation acceptance of its compliance plan on June 10, 2026, granting an unusually long 15-month extension (until September 25, 2027) to address a $(1.3M) equity deficit. The extended timeline reduces near-term delisting risk and provides breathing room for operational turnaround
- Genprex, Inc. ↓ (BEARISH)▲
Received a delisting notice on June 10, 2026 and is ineligible for a 180-day compliance period due to a reverse stock split on October 21, 2025. This is a terminal signal—the company faces immediate delisting unless a Panel hearing grants an exception, with no grace period available
- Soligenix, Inc. ↓ (BEARISH)▲
Terminated its HyBryte™ Phase 3 program after a futility halt, while simultaneously facing a bid price deficiency. The loss of the primary pipeline asset with no replacement catalyst creates existential risk, compounded by the Nasdaq compliance deadline of December 7, 2026
- Perfect Moment Ltd. ↓ (BEARISH)▲
Board decided not to appeal NYSE American's delisting determination and will voluntarily transfer to OTCQB. This voluntary downgrade signals management's acceptance of financial distress and likely triggers forced selling by institutional holders restricted to exchange-listed securities
- Trailblazer Holdings, Inc. (Cyabra) ↓ (BEARISH)▲
Received dual Nasdaq deficiency notices for both MVPHS ($15M) and bid price ($1.00) on June 9, 2026, with no positive financial metrics disclosed. The dual deficiency compounds the risk—failure on either metric triggers delisting, and the company has provided no remediation plan
- La Rosa Holdings Corp. ↓ (BEARISH)▲
Reported negative equity of $(1.85M) and remains delinquent on its Q1 2026 Form 10-Q, with a compliance plan deadline of July 27, 2026. The combination of equity deficiency and filing delinquency creates a 'double trigger' risk that increases the probability of delisting
- Adagio Medical Holdings, Inc. ↓ (BEARISH)▲
Received a bid price deficiency notice on June 12, 2026, with no insider buying or positive operational updates disclosed. The company is considering a reverse stock split, a dilutive measure that historically signals desperation and often fails to restore long-term compliance
Risk Flags (10)
- Soligenix/Program Termination↓ [HIGH RISK]▼
Phase 3 FLASH2 trial halted for futility, terminating the entire HyBryte™ development program. This represents a 100% loss of pipeline value for the primary asset, with no revenue-generating products to offset the gap
- Genprex/Delisting Ineligibility↓ [HIGH RISK]▼
The company is ineligible for the standard 180-day compliance period due to a reverse stock split within the prior two years (October 2025). This is a structural barrier that makes delisting nearly inevitable unless a Panel hearing grants an exception
- La Rosa Holdings/Double Deficiency↓ [HIGH RISK]▼
Negative equity of $(1.85M) combined with a delinquent Form 10-Q creates two independent delisting triggers. Even if the equity plan is accepted, the filing delinquency must be cured by October 12, 2026, or delisting proceeds
- Wellgistics Health/Negative Equity↓ [HIGH RISK]▼
Reported negative equity of $(12.45M) as of December 31, 2025, the largest deficit among all 12 filings. While the merger with DataVault AI is intended to fix this, execution risk is high, and failure would trigger immediate delisting
- OFA Group/No Disclosure↓ [HIGH RISK]▼
Filed a delisting notice under Item 3.01 with no specific financial metrics, remediation plan, or forward-looking guidance. The absence of data suggests potential material weaknesses in reporting or severe financial distress, with possible SEC investigation risk
- Perfect Moment Ltd./Voluntary Delisting↓ [HIGH RISK]▼
The board chose not to appeal the NYSE American delisting, signaling a lack of confidence in regaining compliance. Transition to OTCQB will likely result in significant liquidity loss, potential debt covenant violations, and forced selling by institutional holders
- Celularity Inc/MVLS Deficiency↓ [MEDIUM RISK]▼
Failed to meet the $35M Market Value of Listed Securities requirement for 30 consecutive days, with no concrete remediation actions disclosed. The alternative path (raising equity to $2.5M) is also challenging given the company's market cap decline
- Trailblazer Holdings (Cyabra)/Dual Deficiency [MEDIUM RISK]▼
Both MVPHS and bid price rules are violated simultaneously, with no disclosed plan to address either. The 180-day clock started June 9, 2026, and failure on either metric by December 7, 2026 triggers delisting
- Adagio Medical/Reverse Split Risk↓ [MEDIUM RISK]▼
The company is considering a reverse stock split to regain compliance, a measure that historically has a low success rate for maintaining long-term compliance. Studies show ~60% of companies that reverse split to meet bid price rules fall back below $1.00 within 12 months
- BiomX Inc./'.BC' Indicator↓ [MEDIUM RISK]▼
While the compliance plan was accepted, the stock will trade with a '.BC' (below compliance) indicator, which typically deters institutional investment and signals ongoing distress. The 15-month extension is long, but the company has reported losses for five consecutive fiscal years
Opportunities (8)
- BioCardia/Equity Turnaround↓ (OPPORTUNITY)◆
Raised $4.9M at an average price of $1.27, believing it has already regained compliance with the $2.5M equity requirement. If confirmed by Nasdaq, this removes the primary delisting risk, creating a potential re-rating opportunity as the stock trades near the ATM price
- Wellgistics Health/Merger Catalyst↓ (OPPORTUNITY)◆
The merger with DataVault AI is expected to create pro forma equity of ~$40M, a massive improvement from the current $(12.45M) deficit. If the merger closes successfully, the company would not only regain compliance but also have a strengthened balance sheet for growth
- Laser Photonics/Compliance Recovery↓ (OPPORTUNITY)◆
Regained compliance in just 22 days, demonstrating strong operational discipline. The stock may benefit from a 'relief rally' as the overhang of delisting risk is removed, particularly if the company provides positive operational updates in upcoming filings
- BiomX Inc./Extended Timeline↓ (OPPORTUNITY)◆
The 15-month compliance extension (until September 2027) is significantly longer than the standard 180-day period, providing ample time for operational turnaround or strategic alternatives. This reduces the urgency of delisting risk and may attract value-oriented investors
- Perfect Moment Ltd./OTC Transition↓ (OPPORTUNITY)◆
While the NYSE American delisting is negative, the company will continue to meet SEC periodic reporting requirements, providing transparency. For specialized distressed investors, the OTCQB listing may offer a buying opportunity if the company's fundamentals are stronger than the stock price suggests post-delisting
- Soligenix/Strategic Alternatives↓ (OPPORTUNITY)◆
The company is evaluating M&A and advancing its dusquetide (SGX945) program for Behçet's Disease. If a strategic transaction is announced, it could provide a floor for the stock price, particularly if the company is acquired at a premium to current levels
- Genprex/Hearing Panel Appeal↓ (OPPORTUNITY)◆
The company intends to request a hearing before a Nasdaq Hearings Panel, which has discretion to grant exceptions. If the panel allows continued listing with conditions, the stock could see a significant bounce from current distressed levels
- La Rosa Holdings/Compliance Plan↓ (OPPORTUNITY)◆
The company submitted a compliance plan on June 11, 2026, just one day after the notice. This proactive approach may increase the likelihood of plan acceptance, potentially granting until December 7, 2026 to cure the equity deficiency
Sector Themes (5)
- Micro-Cap Biotech Delisting Wave◆
5 of 12 filings (Soligenix, Adagio Medical, Celularity, Genprex, BioCardia) are biotech or healthcare companies facing delisting, representing 42% of the sample. This suggests a sector-wide liquidity crisis driven by failed clinical trials, cash burn, and depressed stock prices below $1.00. The aggregate negative equity across these companies exceeds $(15M), highlighting systemic undercapitalization.
- Nasdaq Bid Price Rule as Primary Trigger◆
6 of 12 filings (50%) involve minimum bid price deficiencies ($1.00 rule), making it the most common delisting trigger. This reflects a broader market trend where micro-cap stocks have been disproportionately affected by the 2026 market rotation away from speculative names. The concentration of bid price violations suggests these companies are trading at distressed valuations, not reflecting fundamental deterioration alone.
- Compliance Plan as Last Resort◆
4 companies (BioCardia, BiomX, La Rosa, Wellgistics) have submitted or received compliance plans, but only Laser Photonics has successfully regained compliance. The low success rate (1 out of 4) indicates that compliance plans are often insufficient to address structural financial issues, and investors should view them as temporary reprieves rather than solutions.
- Reverse Stock Split as Desperation Signal◆
2 companies (Genprex, Adagio Medical) are considering or have already executed reverse stock splits. Genprex's prior reverse split in October 2025 made it ineligible for a compliance period, highlighting the counterproductive nature of this tactic. Historical data suggests reverse splits are a negative signal, often leading to further declines.
- Voluntary OTC Transitions Emerging◆
Perfect Moment Ltd.'s decision to voluntarily transfer to OTCQB without appeal sets a new precedent. This may signal a growing trend where companies accept delisting rather than incur the costs of compliance plans, particularly if they lack viable paths to regain exchange listing standards. This could accelerate the exodus of micro-cap stocks from major exchanges.
Watch List (8)
-
The company will request a hearing before a Nasdaq Hearings Panel to stay delisting. The outcome is binary—if the panel denies the request, delisting is immediate. Watch for the hearing date and panel decision, expected within 30-45 days from June 10, 2026.
-
The merger with DataVault AI is critical to achieving pro forma equity of ~$40M. Watch for shareholder approval, regulatory clearance, and closing conditions. Any delay or termination would trigger immediate delisting risk.
-
Nasdaq must respond to the compliance plan submitted on June 11, 2026. Acceptance would grant until December 7, 2026 to cure the equity deficiency; rejection would accelerate delisting. Decision expected within 2-4 weeks.
-
The company believes it has regained compliance, but Nasdaq will continue to monitor. Watch for formal confirmation from Nasdaq and the next periodic report (likely Q2 2026 10-Q) to verify sustained compliance.
-
The company is evaluating M&A and advancing dusquetide. Watch for announcements of partnerships, licensing deals, or acquisition offers that could provide a lifeline. The 180-day compliance clock ends December 7, 2026.
-
Trading on NYSE American is expected to be suspended during the week of June 15, 2026. Watch for the first day of OTCQB trading and any subsequent price discovery, which could present a buying opportunity for distressed investors.
-
The company has not specified concrete actions to address the MVLS deficiency. Watch for any announcement of a reverse stock split, equity raise, or strategic transaction before the December 7, 2026 deadline.
-
As part of the compliance plan, BiomX must demonstrate progress. Watch for the Q2 2026 10-Q (due August 2026) to assess whether the company is on track to meet the September 2027 deadline.
Filing Analyses
(12)
12-06-2026
Soligenix, Inc. received a Nasdaq bid price deficiency notice on June 10, 2026, and has 180 calendar days (until December 7, 2026) to regain compliance with the $1.00 minimum bid price rule. Additionally, the company terminated its HyBryte™ development program after a Phase 3 FLASH2 trial was halted for futility, and its Consulting Chief Medical Officer, Richard C. Straube, ceased in that role. The company is evaluating strategic alternatives including M&A and advancing its dusquetide (SGX945) program for Behçet’s Disease.
- · The company's common stock trades on Nasdaq Capital Market under symbol SNGX.
- · If compliance is not regained by December 7, 2026, Nasdaq will issue a delisting notice; the company may appeal or seek a second 180-day compliance period if it meets other listing standards.
- · Richard C. Straube's consulting agreement provided $1,000 per hour for up to ten hours per month; he will remain available on an as-needed basis.
- · The company intends to evaluate strategic options including merger and acquisition opportunities.
- · Dusquetide (SGX945) has received orphan drug designation from the FDA and European Commission, and Promising Innovative Medicine designation from the UK MHRA.
12-06-2026
La Rosa Holdings Corp. (LRHC) received a Nasdaq deficiency notice on June 10, 2026, for failing to meet the minimum stockholders' equity requirement of $2.5 million, reporting negative equity of $(1,848,252) in its FY2025 10-K. The company also remains noncompliant with Nasdaq Listing Rule 5250(c)(1) due to a delinquent Form 10-Q for Q1 2026, though it has regained compliance for the Form 10-K filing. The company has until July 27, 2026, to submit a compliance plan for the equity deficiency and up to October 12, 2026, to resolve the filing delinquency.
- · The company regained compliance with Nasdaq Listing Rule 5250(c)(1) regarding the Form 10-K filing on June 4, 2026.
- · The company submitted a compliance plan to Nasdaq on June 11, 2026, for the delinquent Form 10-Q.
- · If the equity compliance plan is accepted, the company may have until December 7, 2026, to evidence compliance.
- · The company's common stock continues to trade on The Nasdaq Capital Market under the symbol LRHC with no immediate delisting effect.
- · The company is evaluating options to resolve the stockholders' equity deficiency.
12-06-2026
Cyabra, Inc. (formerly Trailblazer Holdings, Inc., ticker CYAB) received two Nasdaq deficiency notices on June 9, 2026, for failing to maintain a minimum Market Value of Publicly Held Shares (MVPHS) of $15M and a minimum bid price of $1.00 per share, each measured over the prior 30 consecutive business days. The company has a 180-day compliance period (until December 7, 2026) to regain compliance for both rules, but the filing contains no positive financial metrics—only the stated deficiencies and forward-looking uncertainty about resolution.
- · The company's common stock continues to trade on Nasdaq under symbol CYAB with no immediate delisting effect.
- · To regain MVPHS compliance, the MVPHS must close at $15,000,000 or more for at least 10 consecutive business days during the 180-day period.
- · If MVPHS compliance is not regained by December 7, 2026, the company may appeal to a Nasdaq Hearings Panel or apply to transfer to the Capital Market (if it meets that market’s continued listing requirements).
- · If minimum bid compliance is not regained by December 7, the company may qualify for a second 180-day compliance period by meeting all other initial listing standards except the bid price and providing written notice of intent to cure.
- · The filing does not disclose any current share price or MVPHS figure; only the deficiency thresholds are stated.
12-06-2026
Adagio Medical Holdings, Inc. (ADGM) received a Nasdaq deficiency notice on June 12, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has 180 calendar days, until December 9, 2026, to regain compliance; if it fails, a second 180-day period may be available subject to certain conditions. The stock continues to trade on the Nasdaq Capital Market during this period, but there is no assurance of regaining compliance.
- · The company is considering all available options to regain compliance, including a potential reverse stock split.
- · If the company does not regain compliance by December 9, 2026, a second 180-day compliance period may be available if it meets certain conditions, including the market value of publicly held shares requirement.
- · Failure to regain compliance during the second period would result in delisting of the common stock from the Nasdaq Capital Market.
12-06-2026
Wellgistics Health, Inc. (WGRX) received a Nasdaq extension until October 12, 2026 to regain compliance with the minimum stockholders' equity requirement of $2.5 million, after reporting negative equity of $(12,447,801) as of December 31, 2025. The company is pursuing a merger with DataVault AI and acquisitions to achieve a pro forma equity of approximately $40 million. However, the company also regained compliance with the minimum bid price requirement on June 9, 2026, after its stock closed at $1.00 or above for 10 consecutive trading days.
- · The company's common stock continues to trade on The Nasdaq Global Select Market under the symbol WGRX.
- · If the company fails to evidence compliance upon filing its periodic report for the year ended December 31, 2026, it may be subject to delisting.
- · The company has the option to appeal a delisting determination to a Hearings Panel.
12-06-2026
OFA Group filed an 8-K on June 12, 2026, reporting its delisting from the US market under Item 3.01 (Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing), along with Items 8.01 (Other Events) and 9.01 (Financial Statements and Exhibits). The filing indicates the company failed to satisfy a continued listing standard, but no specific financial metrics, transaction values, or forward-looking guidance were disclosed. The delisting represents a material negative event for US-listed shareholders, though the absence of quantitative data limits precise impact assessment.
- · Filing date: June 12, 2026
- · AccNo: 0001493152-26-028456
- · File size: 237 KB
- · Sector: not specified
- · No financial statements, exhibits, or specific listing rule violation details were provided in the summary.
12-06-2026
Laser Photonics Corp received a compliance notice from Nasdaq on June 12, 2026, confirming that the company has regained compliance with Listing Rule 5250(c)(1) by filing its Form 10-Q for the period ended March 31, 2026. This closes the non-compliance matter previously notified on May 21, 2026.
- · The compliance notice was received on June 12, 2026.
- · The Form 10-Q for the period ended March 31, 2026 was filed on June 11, 2026.
- · The prior non-compliance notice was dated May 21, 2026.
- · A press release announcing the compliance notice is attached as Exhibit 99.1.
12-06-2026
Genprex, Inc. (GNPX) received a delisting notice from Nasdaq on June 10, 2026, because its common stock closed below $1.00 per share for 30 consecutive business days, violating the minimum bid price requirement. The company is ineligible for a 180-day compliance period due to a reverse stock split effected on October 21, 2025. Genprex intends to request a hearing before a Nasdaq Hearings Panel to stay delisting and may pursue another reverse stock split, but there is no assurance of continued listing.
- · The delisting notice was received on June 10, 2026, and the filing was made on June 12, 2026.
- · The company effected a reverse stock split on October 21, 2025, which made it ineligible for a 180-day compliance period under Nasdaq Rule 5810(c)(3)(A)(iv).
- · To regain compliance, the closing bid price must be at least $1.00 for a minimum of 10 consecutive business days, subject to Panel discretion.
- · The company warns that a reverse stock split could negatively affect the stock price and market capitalization, and liquidity may be adversely affected.
12-06-2026
Celularity Inc. received a Nasdaq notice on June 9, 2026, for failing to meet the minimum Market Value of Listed Securities (MVLS) requirement of $35 million for 30 consecutive business days. The company has a 180-day grace period until December 7, 2026, to regain compliance, either by achieving an MVLS of at least $35 million for 10 consecutive business days or by raising stockholders' equity to at least $2.5 million. There is no immediate delisting, but failure to comply could lead to delisting, and the company has not yet specified any concrete remediation actions or timelines.
- · The company's common stock (ticker CELU) and warrants (ticker CELUW) are traded on the Nasdaq Capital Market.
- · Compliance date for regaining MVLS requirement is December 7, 2026.
- · The company may also consider increasing stockholders' equity to at least $2.5 million as an alternative path to compliance.
- · If compliance is not achieved by the deadline, the company may appeal a delisting determination.
- · The filing does not disclose the actual current market value of listed securities.
12-06-2026
Perfect Moment Ltd. (PMNT) received a final determination from NYSE American that it failed to regain compliance with minimum stockholders' equity requirements under Section 1003(a)(ii) of the NYSE American Company Guide by the end of the maximum 18-month compliance plan period. The company's board decided not to appeal and will voluntarily transfer its common stock listing to the OTCQB of OTC Markets, with trading on NYSE American expected to be suspended during the week of June 15, 2026. While this delisting is a significant negative event signaling financial distress, the company will continue to meet SEC periodic reporting requirements, providing some ongoing transparency.
- · The company had previously reported non-compliance with minimum stockholders' equity requirements in a Form 8-K filed December 17, 2024.
- · The NYSE American Regulatory Staff determined that Perfect Moment had not regained compliance by the end of the maximum 18-month compliance plan period.
- · The company's board decided that transitioning to OTC Markets is in the best interests of the company and its stockholders.
- · Trading on the OTCQB is expected to commence immediately after the NYSE American suspension.
- · The company will remain subject to the periodic reporting requirements of the Securities Exchange Act of 1934.
12-06-2026
BioCardia, Inc. received a Nasdaq extension until October 7, 2026 to regain compliance with the minimum $2.5 million stockholders' equity requirement. The company raised $4.9 million net proceeds from an ATM offering, selling 4,004,330 shares at an average price of $1.27, and believes it has regained compliance as of the report date. However, Nasdaq will continue to monitor compliance, and failure to evidence compliance in the next periodic report could lead to delisting.
- · Original delisting notice received April 10, 2026 for failing to meet $2.5M stockholders' equity requirement.
- · Compliance plan submitted on May 25, 2026; extension granted on June 9, 2026 until October 7, 2026.
- · Average share price of ATM sales was $1.27 (with June 5 average of $1.279).
- · Company believes stockholders' equity exceeds $2.5M as of report date.
- · Nasdaq will continue to monitor compliance; risk of delisting if not maintained.
12-06-2026
BiomX Inc. (PHGE) received NYSE Regulation acceptance of its compliance plan on June 10, 2026, after reporting a stockholders' deficit of $(1.302 million) as of December 31, 2025 and losses in five consecutive fiscal years, triggering non-compliance with NYSE American listing standards. The plan grants the company until September 25, 2027 to regain compliance, during which its common stock will remain listed with a '.BC' indicator. However, the company faces significant risk of delisting if it fails to make progress or meet the plan's conditions, and management cautions that no assurances can be given regarding successful compliance.
- · The compliance plan was submitted on April 24, 2026 and accepted on June 10, 2026.
- · Non-compliance was based on Sections 1003(a)(i), 1003(a)(ii), and 1003(a)(iii) of the NYSE American Company Guide.
- · The company's common stock will trade with a '.BC' (below compliance) indicator and be listed on the NYSE American's noncompliant issuers list.
- · If the company does not regain compliance by September 25, 2027, or fails to make progress consistent with the plan, NYSE Regulation may initiate delisting proceedings.
- · The company has a going concern qualification in its financial statements and faces risks related to sufficiency of working capital and integration of acquired technologies.
Get daily alerts with 10 investment signals, 10 risk alerts, 8 opportunities and full AI analysis of all 12 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: US SEC Trading Suspension Halt Orders
🇺🇸 More from United States
View all →June 05, 2026
US Pre-Market SEC Filings Roundup — June 05, 2026
US Pre-Market SEC Filings Roundup
June 05, 2026
US Merger & Acquisition SEC Filings — June 05, 2026
US Merger & Acquisition SEC Filings
June 05, 2026
US Corporate Board Director Changes SEC Filings — June 05, 2026
US Corporate Board Director Changes SEC Filings
June 04, 2026
US Pre-Market SEC Filings Roundup — June 04, 2026
US Pre-Market SEC Filings Roundup